Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study supports tailoring adjuvant therapy for early-stage breast cancer

17.12.2003


Premenopausal women with lymph node-negative breast cancer should receive adjuvant therapy tailored according to the estrogen receptor status of the primary tumor, concludes a study by the International Breast Cancer Study Group (IBCSG) reported in the December 17 issue of the Journal of the National Cancer Institute.



Patients with estrogen receptor (ER)-negative (i.e., endocrine nonresponsive) breast cancer should receive adjuvant chemotherapy, according to the study, whereas for patients with ER-positive (i.e., endocrine responsive) tumors, the use of endocrine therapy alone or in combination with adjuvant chemotherapy requires further study.

Some studies have suggested that cytotoxic chemotherapy benefits premenopausal women with breast cancer because it causes premature menopause. The new study addresses whether adjuvant ovarian function suppression can be used as a replacement for or as a supplement to cytotoxic adjuvant chemotherapy for premenopausal women with early-stage breast cancer.


These findings support the idea that ovarian suppression "is a viable treatment alternative for at least some premenopausal women with breast cancer," comment Joseph L. Pater, M.D., and Wendy R. Parulekar, M.D., of the National Cancer Institute of Canada Clinical Trials Group at Queen’s University in Kingston, Ontario, in an accompanying editorial.

In the study, Monica Castiglione-Gertsch, M.D., and her colleagues from the IBCSG, compared outcomes of 1,063 pre- and perimenopausal women who were previously treated for lymph-node negative (early-stage) breast cancer and randomly assigned to receive adjuvant chemotherapy, adjuvant therapy with the ovarian function suppression drug goserelin, or adjuvant chemotherapy followed by goserelin. The women were tested to determine the estrogen receptor status of their tumors.

After a median follow-up of 7 years, there was no difference in disease-free survival or overall survival among patients in the three treatment groups. However, a subgroup analysis revealed that patients with ER-negative tumors who received chemotherapy alone or followed by goserelin had better disease-free survival than patients who received goserelin alone. By contrast, among patients with ER-positive tumors, results were similar after chemotherapy alone or goserelin alone. Sequential use of chemotherapy followed by goserelin resulted in a statistically nonsignificant benefit that was limited to younger women.

The authors caution that their findings "should not alter current patient care, but rather emphasize the relevance of current studies of chemotherapy and endocrine agents." The editorialists agree, recommending that future studies examine the selective use of ovarian suppression in women who are not rendered menopausal by chemotherapy.


Contact: Monica Castiglione-Gertsch, M.D., International Breast Cancer Study Group, 41-31-389-9191; fax: 41-31-389-9200, monica.castiglione@siak.ch.

To interview coauthor Richard Gelber, contact Janet Haley-Dubow, Dana-Farber Cancer Institute, 617-632-5665, janet_haley@dfci.harvard.edu.

Editorial: Nancy Dorrance, Queen’s University, 613-533-2869, dorrance@post.queensu.ca.
International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node–negative breast cancer: A randomized trial. J Natl Cancer Inst 2003;95:1833–46.

Editorial: Pater JL, Parulekar WR. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward. J Natl Cancer Inst 2003;95:1811–2.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oupjournals.org/.

Katherine Arnold | EurekAlert!
Further information:
http://jncicancerspectrum.oupjournals.org

More articles from Health and Medicine:

nachricht Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine

nachricht Breakthrough in understanding how deadly pneumococcus avoids immune defenses
13.11.2018 | University of Liverpool

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

How algae and carbon fibers could sustainably reduce the athmospheric carbon dioxide concentration

14.11.2018 | Life Sciences

NIH scientists illuminate causes of hepatitis b virus-associated acute liver failure

14.11.2018 | Life Sciences

The unintended consequences of dams and reservoirs

14.11.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>